{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:39:26Z","timestamp":1792611566199,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,28]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To revise the 2017 clinical practice guidelines (CPG) for the management of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) to reflect advancements in the field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Similar to the 2017 CPG, the Grading of Recommendations, Assessment, Development, and Evaluation system was adopted for this revision. The intended users of this CPG include patients diagnosed with MPA or GPA in Japan and their families and healthcare professionals, including specialists and non-specialists. Based on a scoping review, four clinical questions (CQs) of the 2017 guidelines were modified, and six new CQs were added.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We suggest a combination of glucocorticoid and cyclophosphamide or rituximab for remission induction therapy. In cases where cyclophosphamide or rituximab is used, we suggest the use of avacopan over high-dose glucocorticoid. Furthermore, we suggest against the use of plasma exchange in addition to the standard treatment in severe cases of MPA\/GPA. Finally, we suggest the use of glucocorticoid and rituximab over glucocorticoid and azathioprine for remission maintenance therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The recommendations have been updated based on patient preference, certainty of evidence, benefit and risk balance, and cost.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/road081","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:31:11Z","timestamp":1691800271000},"page":"559-567","source":"Crossref","is-referenced-by-count":21,"title":["Clinical practice guidelines of\u00a0the Japan Research Committee of\u00a0the Ministry of\u00a0Health, Labour, and\u00a0Welfare for\u00a0Intractable\u00a0Vasculitis for\u00a0the management of\u00a0microscopic polyangiitis and\u00a0granulomatosis with polyangiitis: The 2023 update \u2013 secondary publication"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-0818","authenticated-orcid":false,"given":"Ken-ei","family":"Sada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ome Municipal General Hospital , Ome, Japan"},{"name":"Department of Rheumatology, Tokyo Medical and Dental University (TMDU) , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kaname","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishu","family":"Nango","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Seibo International Catholic Hospital , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Kishibe","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University , Asahikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University , Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiju","family":"Hiromura","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine , Maebashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamihiro","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Tohoku Medical and Pharmaceutical University , Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Bando","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University , Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[{"name":"Kanazawa University , Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University , Kawagoe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohko","family":"Murakawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Shimane University Faculty of Medicine , Izumo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Department of Clinical Epidemiology, Kochi Medical School , Nankoku, Japan"},{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"2024052809320344600_R1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of\u00a0Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024052809320344600_R2","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for\u00a0the management of\u00a0ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024052809320344600_R3","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of\u00a0Rheumatology\/Vasculitis Foundation Guideline for\u00a0the Management of\u00a0Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024052809320344600_R4","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and\u00a0BHPR guideline for\u00a0the management of\u00a0adults with ANCA-associated vasculitis","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2024052809320344600_R5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3899\/jrheum.130602","article-title":"Comparison of\u00a0phenotype and\u00a0outcome in\u00a0microscopic polyangiitis between Europe and\u00a0Japan","volume":"41","author":"Furuta","year":"2014","journal-title":"J Rheumatol"},{"key":"2024052809320344600_R6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3899\/jrheum.160005","article-title":"Comparison of\u00a0the phenotype and\u00a0outcome of\u00a0granulomatosis with polyangiitis between UK and\u00a0Japanese cohorts","volume":"44","author":"Furuta","year":"2017","journal-title":"J Rheumatol"},{"key":"2024052809320344600_R7","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","article-title":"Comparison of\u00a0the epidemiology of\u00a0anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and\u00a0the U.K","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2024052809320344600_R8","first-page":"474","article-title":"Guideline for\u00a0management of\u00a0vasculitis syndrome (JCS 2008). Japanese Circulation Society","volume":"75","author":"J. C. S. Joint Working Group","year":"2011","journal-title":"Circ J"},{"key":"2024052809320344600_R9","article-title":"Research Committee of\u00a0Intractable\u00a0Vasculitis Syndrome and\u00a0the Research Committee of\u00a0Intractable\u00a0Renal Disease of\u00a0the Ministry of\u00a0Health, Labour and\u00a0Welfare","volume-title":"Clinical practice guideline for ANCA-associated Vasculitis (In Japanese)","author":"Hirofumi","year":"2014"},{"key":"2024052809320344600_R10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2018.1500437","article-title":"2017 Clinical practice guidelines of\u00a0the Japan Research Committee of\u00a0the Ministry of\u00a0Health, Labour, and\u00a0Welfare for\u00a0Intractable\u00a0Vasculitis for\u00a0the management of\u00a0ANCA-associated vasculitis","volume":"29","author":"Harigai","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2024052809320344600_R11","author":"Masayoshi"},{"key":"2024052809320344600_R12","article-title":"Systematic review and\u00a0meta-analysis for\u00a02023 clinical practice guidelines of\u00a0the Japan research committee of\u00a0the ministry of\u00a0health, labour, and\u00a0welfare for\u00a0intractable vasculitis for\u00a0the management of\u00a0ANCA-associated vasculitis","author":"Watanabe","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024052809320344600_R13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in\u00a0ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med Massachusetts Medical Society"},{"key":"2024052809320344600_R14","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in\u00a0ANCA-associated renal vasculitis: 2-year results of\u00a0a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024052809320344600_R15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for\u00a0the induction of\u00a0remission in\u00a0nonlife-threatening relapses of\u00a0antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial","volume":"14","author":"Tuin","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024052809320344600_R16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for\u00a0remission induction in\u00a0ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024052809320344600_R17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324364","article-title":"Effects of\u00a0mycophenolate mofetil combined with corticosteroids for\u00a0induction therapy of\u00a0microscopic polyangiitis","volume":"33","author":"Han","year":"2011","journal-title":"Am J Nephrol"},{"key":"2024052809320344600_R18","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclophosphamide for\u00a0inducing remission of\u00a0ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2024052809320344600_R19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and\u00a0glucocorticoids in\u00a0severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2024052809320344600_R20","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of\u00a0reduced-dose vs\u00a0high-dose glucocorticoids added to rituximab on\u00a0remission induction in\u00a0ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"2024052809320344600_R21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for\u00a0the treatment of\u00a0ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2024052809320344600_R22","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of\u00a0C5a receptor inhibitor avacopan in\u00a0ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024052809320344600_R23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/ajkd.2002.29874","article-title":"Predictive value of\u00a0initial histology and\u00a0effect of\u00a0plasmapheresis on\u00a0long-term prognosis of\u00a0rapidly progressive glomerulonephritis","volume":"39","author":"Z\u00e4uner","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2024052809320344600_R24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ndt\/gfq360","article-title":"Plasma exchange for\u00a0induction and\u00a0cyclosporine A for\u00a0maintenance of\u00a0remission in\u00a0Wegener\u2019s granulomatosis \u2013 a clinical randomized controlled trial","volume":"26","author":"Szpirt","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2024052809320344600_R25","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for\u00a0maintenance in\u00a0ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2024052809320344600_R26","first-page":"S54","article-title":"Rituximab versus azathioprine for\u00a0ANCA-associated vasculitis maintenance therapy: impact on\u00a0global disability and\u00a0health-related quality of\u00a0life","volume":"34","author":"Pugnet","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2024052809320344600_R27","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of\u00a0remission-maintenance regimens for\u00a0ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024052809320344600_R28","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of\u00a0individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of\u00a0a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024052809320344600_R29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of\u00a0antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024052809320344600_R30","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of\u00a0prolonged treatment in\u00a0the remission phase of\u00a0ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024052809320344600_R31","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","article-title":"Extended versus standard azathioprine maintenance therapy in\u00a0newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of\u00a0remission: a randomised clinical trial","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2024052809320344600_R32","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and\u00a0safety of\u00a0belimumab and\u00a0azathioprine for\u00a0maintenance of\u00a0remission in\u00a0antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024052809320344600_R33","article-title":"Concordance between practice and\u00a0published evidence in\u00a0the management of\u00a0ANCA-associated vasculitis in\u00a0Japan: a cross-sectional web-questionnaire survey","author":"Miyawaki","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024052809320344600_R34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for\u00a0ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/road081\/51249436\/road081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/3\/559\/57944650\/road081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/3\/559\/57944650\/road081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T05:34:30Z","timestamp":1716874470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/3\/559\/7246512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,7,28]]},"published-print":{"date-parts":[[2024,3,28]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/road081","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2023,7,28]]}}}